Launching a new product in schizophrenia

Since 2016, we have been working with a top ten pharmaceutical company in both the UK and Europe (EMEA) to launch a new product in schizophrenia.

The product is a unique treatment to revolutionise how patients with schizophrenia receive their medication, and wider aspects of care. We have supported our client to execute a comprehensive launch plan to reach customers at all levels and in multiple geographies across Europe.

Attigo have delivered launch activities through a multi-channel approach; organising local meetings, national and Europe-wide conferences and creating digital platforms on which to engage with healthcare professionals. These have been followed-up with value-added services such as generating call-back opportunities for sales teams, writing and designing educational leave pieces and publishing an advertorial.

We are continuing to work with our client on the growth of their product range in neuroscience throughout 2017, including developing targeted marketing materials to continue to address healthcare professionals’ and patients’ needs in this therapy area.

If you would like to find out more about how we work to increase clients’ market footprint with specific groups, feel free to get in touch with us via mail@attigo.me – we’d be delighted to hear from you.